Human OKT3 scFv Stable Cell Line - A549

The OKT3 scFv (single-chain variable fragment) is derived from the murine monoclonal antibody Muromonab-CD3, the first antibody-based therapeutic approved for human use, which specifically targets the CD3 epsilon chain of the T-cell receptor complex. The Human OKT3 scFv Stable Cell Line - A549 is generated by transfecting the A549 cell line, a human lung adenocarcinoma epithelial cell line widely used as a model in cancer and immunology research, with a lentiviral or plasmid vector carrying the codon-optimized OKT3 scFv gene sequence. Following antibiotic selection and single-cell cloning, a population of cells that constitutively and uniformly express the OKT3 scFv on the cell surface or secrete it into the culture supernatant is established. This genetically modified cell line provides a reliable and reproducible in vitro tool for studying CD3-targeting interactions, bypassing the need for transient transfection and ensuring consistent expression levels across passages.

This stable cell line has broad applications in both basic and translational research. It is particularly valuable for evaluating the binding activity and specificity of anti-CD3 antibodies or CD3-targeting biologics, including bispecific T-cell engagers and CAR-T constructs, where the OKT3 scFv serves as a positive control or a target antigen. Researchers can use this cell line in flow cytometry, ELISA, and cell-based binding assays to characterize antibody-antigen interactions, assess cross-reactivity, and screen for novel CD3-binding molecules. Additionally, the A549 background makes it suitable for studying the functional impact of CD3 engagement in the context of a lung cancer cell environment, including downstream signaling, cytokine release, and immune cell activation. The stable nature of the expression system also supports long-term experimental designs, high-throughput screening campaigns, and the generation of consistent data sets for preclinical evaluation of immunotherapeutic candidates.